Iv%2525252525252525252525252520gentamicin

# IV Gentamicin ## Overview Gentamicin is an aminoglycoside antibiotic that exerts bactericidal activity by binding to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. It provides excellent coverage against aerobic gram-negative bacilli (including *Pseudomonas aeruginosa*). ## Primary Indications * Serious systemic infections (e.g., sepsis, intra-abdominal infections, complicated UTIs, pyelonephritis). * Synergistic treatment of gram-positive endocarditis (e.g., *Staphylococcus* or *Enterococcus* species). * Febrile neutropenia (in combination with other agents). ## Adult Dosing * **Conventional Dosing:** 1–2.5 mg/kg every 8–12 hours. * **Extended Interval Dosing (EID):** 5–7 mg/kg every 24 hours (dependent on renal function). * **Synergy Dosing (Endocarditis):** 1 mg/kg every 8–12 hours (typically capped at 80 mg per dose; often adjusted based on levels). * *Note: Dosing should always be based on local hospital protocol.* ## Pediatric Dosing * **Neonates (Post-menstrual age dependent):** 2.5–5 mg/kg per dose, frequency determined by gestational age (every 18–48 hours). * **Infants/Children:** 2.5 mg/kg every 8 hours. * **EID (Children > 3 months):** 7.5 mg/kg once daily. * *Note: Pediatric dosing requires strict adherence to institutional protocols and pharmacological consultation.* ## Dose Adjustments * **Renal Impairment:** Required for both dose reduction and interval extension. Calculated based on CrCl or GFR. * **Obesity:** Use Adjusted Body Weight (AdjBW) for calculations if patient is significantly overweight, though institutional policies vary widely. ## Contraindications * Hypersensitivity to aminoglycosides. * History of severe myasthenia gravis (may exacerbate neuromuscular blockade). ## Adverse Effects * **Nephrotoxicity:** Usually reversible; associated with trough accumulation. * **Ototoxicity:** Vestibular (vertigo) and auditory (high-frequency hearing loss); often irreversible. * **Neuromuscular Blockade:** Rare, but potentially life-threatening if rapid infusion occurs. ## Key Drug Interactions * **Nephrotoxic drugs:** Amphotericin B, NSAIDs, Vancomycin, Loop diuretics (increased risk of renal failure). * **Neuromuscular blocking agents:** Potentiation of effects. * **Ototoxic drugs:** Ethacrynic acid, furosemide (increased risk of hearing loss). ## Monitoring * **Serum Concentrations:** * *Conventional:* Measure peak (30 min post-infusion) and trough (immediately pre-dose). * *EID:* Random level 6–14 hours post-dose (utilize Hartford Nomogram or similar). * **Renal Function:** Monitor baseline and serial Serum Creatinine/BUN. * **Hearing/Balance:** Periodic assessment of auditory/vestibular function if therapy extends beyond 7–10 days. ## Clinical Pearls * **Volume of Distribution:** Aminoglycosides are hydrophilic; ensure adequate dosing in patients with significant edema, burns, or ascites. * **Administration:** Infuse slowly over 30–60 minutes to reduce neuromuscular blockade risk. * **Synergy:** When used for synergy, levels are generally lower and monitored less frequently than for empiric gram-negative coverage. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by institution. Always verify dosages, contraindications, and monitoring protocols against your local hospital formulary and current clinical guidelines (e.g., Sanford Guide, Lexicomp, or UpToDate) before prescribing or administering medication.